Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Incidence and prevalence of neuromyelitis optica spectrum disorders in Slovakia.
Szilasiová J, Gazda J, Cimprichová A, Cvengrošová A, Donáth V, Fedičová M, Gurčík L, Hančinová V, Jurčaga F, Kahancová E, Kantorová E, Karlík M, Klímová E, Kováčová S, Krastev G, Megová A, Michalík J, Mikula P, Snopeková Ľ, Števková Z. Szilasiová J, et al. Among authors: hancinova v. Neurol Res. 2022 Jan;44(1):38-46. doi: 10.1080/01616412.2021.1952741. Epub 2021 Jul 14. Neurol Res. 2022. PMID: 34261427
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment.
Kantorová E, Vítková M, Martiníková M, Cimprichová A, Fedicˇová M, Kovácˇová S, Mako M, Cisár J, Hancˇinová V, Szilasiová J, Koleda P, RoháIˇová J, Polóniová J, Karlík M, Slezáková D, Klímová E, Maciak M, Kurcˇa E, Hnilicová P. Kantorová E, et al. Among authors: hancinova v. Ther Adv Neurol Disord. 2024 Oct 28;17:17562864241285556. doi: 10.1177/17562864241285556. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39494112 Free PMC article.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.